Department of Neurology, the Second Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi 030000, People's Republic of China.
Shanxi Medical University, Taiyuan, Shanxi 030000, People's Republic of China.
Exp Neurol. 2021 Jul;341:113692. doi: 10.1016/j.expneurol.2021.113692. Epub 2021 Mar 13.
Triggering receptor expressed on myeloid cells-1 (TREM-1) was found to be induced in the context of subarachnoid hemorrhage (SAH) before. This study further investigates its role in the development of SAH-induced early brain injury (EBI). Firstly, rats were randomly divided into Sham and SAH groups for analysis of temporal patterns and cellular localization of TREM-1. Secondly, TREM-1 intervention was administrated to produce Sham, vehicle, antagonist and agonist groups, for analyzing TREM-1, Toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88) and NF-κB expressions at 24 h post-modeling, and EBI assessment at 24 h and 72 h. Thirdly, TLR4 inhibitor (TAK-242) was exploited to produce Sham, Sham+TAK-242, SAH, and SAH + TAK-242 groups to analyze the effects of TLR4 inhibition on TREM-1 induction and EBI evaluation at 72 h. Fourthly, the relationship of soluble TREM-1 (sTREM-1) levels in cerebrospinal fluid of SAH patients with Hunt-Hess grades were explored. The results showed that TREM-1 increased in the brain after experimental SAH (eSAH) early at 6 h and peaked at 48 h, which was found to be located in microglia and endothelial cells. TREM-1 inhibition attenuated EBI associated with TLR4/MyD88/NF-κB suppression, while enhancement had the opposite effects. Contrarily, TLR4 inhibition prevented TREM-1 induction and ameliorated EBI. In addition, sTREM-1 levels in SAH patients positively correlated with Hunt-Hess grades. Overall, the present study provides new evidence that TREM-1 increases dynamically in the brain after eSAH and it is located in microglia and endothelial cells, which may aggravate EBI by interacting with TLR4 pathway. And sTREM-1 in patients might act as a monitoring biomarker of EBI, providing new insights for future studies.
髓样细胞表达触发受体-1(TREM-1)在蛛网膜下腔出血(SAH)前被发现被诱导。本研究进一步研究了其在蛛网膜下腔出血诱导早期脑损伤(EBI)发展中的作用。首先,大鼠随机分为假手术和 SAH 组,分析 TREM-1 的时间模式和细胞定位。其次,给予 TREM-1 干预产生假手术、载体、拮抗剂和激动剂组,分析 24 小时后模型、EBI 评估 24 小时和 72 小时 TREM-1、Toll 样受体 4(TLR4)、髓样分化因子 88(MyD88)和 NF-κB 的表达。第三,利用 TLR4 抑制剂(TAK-242)产生假手术、假手术+TAK-242、SAH 和 SAH+TAK-242 组,分析 TLR4 抑制对 72 小时 TREM-1 诱导和 EBI 评价的影响。第四,探讨了 SAH 患者脑脊液中可溶性 TREM-1(sTREM-1)水平与 Hunt-Hess 分级的关系。结果表明,实验性蛛网膜下腔出血(eSAH)后大脑中 TREM-1 早期增加,6 小时增加,48 小时达到峰值,发现位于小胶质细胞和内皮细胞中。TREM-1 抑制减轻与 TLR4/MyD88/NF-κB 抑制相关的 EBI,而增强则产生相反的作用。相反,TLR4 抑制可预防 TREM-1 诱导并改善 EBI。此外,SAH 患者的 sTREM-1 水平与 Hunt-Hess 分级呈正相关。总之,本研究提供了新的证据,表明 eSAH 后大脑中 TREM-1 动态增加,位于小胶质细胞和内皮细胞中,可能通过与 TLR4 途径相互作用加重 EBI。并且患者的 sTREM-1 可能作为 EBI 的监测生物标志物,为未来的研究提供新的见解。